CVE:TLT Theralase Technologies (TLT) Stock Price, News & Analysis C$0.18 0.00 (0.00%) As of 05/1/2025 10:36 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesBuy This Stock About Theralase Technologies Stock (CVE:TLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Theralase Technologies alerts:Sign Up Key Stats Today's RangeC$0.17▼C$0.1850-Day RangeC$0.17▼C$0.2652-Week RangeC$0.14▼C$0.38Volume25,512 shsAverage Volume114,459 shsMarket CapitalizationC$42.61 millionP/E RatioN/ADividend Yield1,657.14%Price TargetN/AConsensus RatingN/A Company OverviewTheralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.Read More… Receive TLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address TLT Stock News HeadlinesTheralase uncovers new use-case for flagship drugApril 29 at 12:08 AM | msn.comTheralase Discovers New Mechanism of Action of Lead DrugApril 28, 2025 | markets.businessinsider.comTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what could be the biggest wealth opportunity since Bitcoin's early days.May 2, 2025 | Crypto 101 Media (Ad)Theralase Technologies Secures $CAN 419,124 in Private Placement to Boost Cancer and Virus ResearchApril 14, 2025 | tipranks.comRuvidar More Effective in the Treatment of Herpes than FDA-Approved TreatmentsApril 10, 2025 | markets.businessinsider.comRuvidar Demonstrates 7 Year Complete ResponseApril 7, 2025 | markets.businessinsider.comRuvidar Effective in the Treatment of HerpesMarch 24, 2025 | markets.businessinsider.comTheralase's Ruvidar excels in preclinical herpes treatmentMarch 24, 2025 | msn.comSee More Headlines TLT Stock Analysis - Frequently Asked Questions How have TLT shares performed this year? Theralase Technologies' stock was trading at C$0.27 at the start of the year. Since then, TLT stock has decreased by 34.0% and is now trading at C$0.18. View the best growth stocks for 2025 here. How do I buy shares of Theralase Technologies? Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Theralase Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theralase Technologies investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Alphabet (GOOG), Netflix (NFLX), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolCVE:TLT CIKN/A Webtheralase.com Phone+1-416-6995273FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-4,492,945.96 Net Margins-438.78% Pretax MarginN/A Return on Equity-225.69% Return on Assets-81.88% Debt Debt-to-Equity Ratio14.85 Current Ratio1.91 Quick Ratio3.40 Sales & Book Value Annual SalesC$1.02 million Price / Sales41.62 Cash FlowC$0.01 per share Price / Cash Flow30.45 Book ValueC$0.01 per share Price / Book19.20Miscellaneous Outstanding Shares243,507,931Free FloatN/AMarket CapC$42.61 million OptionableNot Optionable Beta1.36 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (CVE:TLT) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theralase Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theralase Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.